1-Phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivatives and related compounds as factor xa inhibitors for the treatment of acute vascular diseases

A compound of formula (I):

• wherein:
• R1 represents a group selected from:
• each ring of which optionally contains a further heteroatom N,
• Z represents an optional substituent halogen,
• alk represents alkylene or alkenylene,
• T represents S, O or NH;
• R2 represents —C1-6alkyl, —C1-3alkylCN, —C0-3alkylRc, —C1-3alkylRf, —C2-3alkylNRaRb, —C2-3alkylOC1-6alkyl, —C2-3alkylOC1-3alkylCONRaRb, with the proviso that R2 does not represent C2-3alkylmorpholino;
• Ra and Rb independently represent hydrogen, —C1-6alkyl, or together with the N atom to which they are bonded form a 5-, 6- or 7-membered non-aromatic heterocyclic ring optionally containing an additional heteroatom selected from O, N or S optionally substituted by —C1-4alkyl, and optionally the S heteroatom is substituted by 0 i.e. represents S(O)n;
• Rc represents —C1-4cycloalkyl;
• Rf represents phenyl or a 5- or 6-membered aromatic heterocyclic ring, containing at least one heteroatom selected from O, N or S, optionally substituted by 0 to 2 groups selected from —C1-4alkyl or —NH2, and optionally the S or N heteroatom is substituted by 0, i.e. represents S(O), or N-oxide;
• n represents 0-2;
• X represents phenyl or a 5- or 6-membered aromatic heterocyclic group containing at least one heteroatom selected from O, N or S, each of which is optionally substituted by 0-2 groups selected from:
• halogen, —C1-4alkyl, —C2-4alkenyl, —CN, —CF3, —NRaRb, —C1-4alkylORa, —C(O)Rd and —C(O)NRaRb;
• R represents hydrogen or —C1-4alkyl;
• Y represents a substituent selected from hydrogen, halogen, —C1-4alkyl, —C2-4alkenyl, —NRaRb, —NO2, —C(O)NRaRb, —N(C1-4alkyl)(CHO), —NHCOC1-4alkyl, —NHSO2RC0-4alkylRO, —C(O)Rd, —S(O)nRd, or —S(O)2NRaRb;
• Rd represents —C1-6alkyl;
• and/or pharmaceutically acceptable derivative thereof.